- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04097938
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667
July 16, 2020 updated by: Galapagos NV
A First-in-human Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3667 in Adult, Healthy, Male Subjects
This study is a first-in-human, Phase I, randomized, double-blind, placebo-controlled, single-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of GLPG3667 after oral single ascending doses (SAD) of GLPG3667 (part 1) and after oral multiple ascending doses (MAD) for 13 days of GLPG3667 (part 2) in healthy male subjects.
In addition, the effect of food (FE) on safety, tolerability, and PK of GLPG3667 oral suspension will be evaluated (part 3 - will not be completed), and the relative bioavailability (rBA) of the capsule versus the oral suspension with the effect of food on the bioavailability of the capsule (part 4), both part 3 and 4 using an open-label, randomized, crossover design.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Antwerp, Belgium, 2060
- SGS Belgium NV - Clinical Pharmacology Unit Antwerp
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male between 18-55 years of age (extremes included), on the date of signing the informed consent form (ICF)
- A body mass index (BMI) between 18-30 kg/m2, inclusive
- Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and fasting clinical laboratory safety tests, available at screening and prior to randomization. Hemoglobin, neutrophil, lymphocyte, and platelet counts must be above the lower limit of normal range. Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must be within normal ranges. Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator
Exclusion Criteria:
- Known hypersensitivity to Investigational Medicinal Product (IMP) ingredients or history of a significant allergic reaction to IMP ingredients as determined by the investigator
- Known contraindication or hypersensitivity to Interferon-alpha (IFN-α) or any component of Intron-A® (Note: this criterion is only applicable to subjects in the MAD part)
- Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or history of hepatitis from any cause with the exception of hepatitis A that was resolved at least 3 months prior to first dosing of the IMP.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo SAD
Single doses of placebo
|
Placebo oral suspension
|
EXPERIMENTAL: GLPG3667 SAD
Single doses of GLPG3667 at up to 6 dose levels in ascending order
|
GLPG3667 oral suspension
|
EXPERIMENTAL: GLPG3667 MAD
Multiple doses of GLPG3667 at up to 3 dose levels in ascending order, daily for 13 days
|
GLPG3667 oral suspension
|
PLACEBO_COMPARATOR: Placebo MAD
Multiple doses of placebo
|
Placebo oral suspension
|
EXPERIMENTAL: GLPG3667 FE fasted
Single dose of GLPG3667 in fasted state
|
GLPG3667 oral suspension
|
EXPERIMENTAL: GLPG3667 FE fed
Single dose of GLPG3667 in fed state
|
GLPG3667 oral suspension
|
EXPERIMENTAL: GLPG3667 oral suspension rBA-FE fed
Single dose of GLPG3667 oral suspension in fed state
|
GLPG3667 oral suspension
|
EXPERIMENTAL: GLPG3667 capsules rBA-FE fasted
Single dose of GLPG3667 capsules in fasted state
|
GLPG3667 capsules
|
EXPERIMENTAL: GLPG3667 capsules rBA-FE fed
Single dose of GLPG3667 capsules in fed state
|
GLPG3667 capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events, and TEAEs leading to treatment discontinuations
Time Frame: From screening through study completion, an average of 5 months
|
To evaluate the safety and tolerability of single and multiple ascending oral doses of GLPG3667, in adult, healthy, male subjects compared with placebo
|
From screening through study completion, an average of 5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma concentration (Cmax) of GLPG3667 (μg/mL)
Time Frame: Between Day 1 pre-dose and Day 16
|
To evaluate the pharmacokinetics (PK) of single and multiple ascending oral doses of GLPG3667, in adult, healthy, male subjects
|
Between Day 1 pre-dose and Day 16
|
Area under curve (AUC) of GLPG3667 (μg.h/mL)
Time Frame: Between Day 1 pre-dose and Day 16
|
To evaluate the PK of single and multiple ascending oral doses of GLPG3667, in adult, healthy, male subjects
|
Between Day 1 pre-dose and Day 16
|
Terminal elimination half-life (t1/2) of GLPG3667 (h)
Time Frame: Between Day 1 pre-dose and Day 16
|
To evaluate the PK of single and multiple ascending oral doses of GLPG3667, in adult, healthy, male subjects
|
Between Day 1 pre-dose and Day 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 18, 2019
Primary Completion (ACTUAL)
March 4, 2020
Study Completion (ACTUAL)
July 6, 2020
Study Registration Dates
First Submitted
September 19, 2019
First Submitted That Met QC Criteria
September 19, 2019
First Posted (ACTUAL)
September 20, 2019
Study Record Updates
Last Update Posted (ACTUAL)
July 17, 2020
Last Update Submitted That Met QC Criteria
July 16, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- GLPG3667-CL-101
- 2019-001659-38 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on GLPG3667 oral suspension
-
Galapagos NVCompleted
-
AstraZenecaCompleted
-
Galapagos NVRecruitingSystemic Lupus ErythematosusUnited States, Spain, Bulgaria, France, Georgia, Argentina, Poland, Hungary, Germany, Chile
-
reMYNDRecruitingAlzheimer DiseaseNetherlands, Spain
-
Galapagos NVRecruitingDermatomyositisUnited States, Belgium, Italy, Chile, Spain, Poland, United Kingdom, Bulgaria, Romania, Croatia, Czechia, France, Argentina
-
Galapagos NVCompleted
-
Galapagos NVCompletedPlaque PsoriasisPoland, Slovakia, Bulgaria
-
Glock Health, Science and Research GmbHCompleted
-
AstraZenecaCompletedHealthy Subjects | Pharmacokinetics | Tolerability | SafetyUnited Kingdom